- Al Gore’s climate-changers at EPA hearings foiled by cool temperatures
- Army’s 3-D printed bombs will create ‘a whole new universe’ of deadly capabilities
- Hamas calls on Hezbollah to join in fight against Israel
- Senators to FIFA, others: Don’t reward Putin with the World Cup in 2018
- U.S. condemns Israeli shelling of shelter in Gaza
- Obamacare shoots premiums up by 88 percent in California
- Chicken pox outbreak puts illegal immigrant facility on lockdown
- Obama to Republicans: ‘Stop just hatin’ all the time’
- U.S. chemical sites vulnerable despite millions spent on security: Congress
- Driverless cars to hit the British streets by 2015
Supreme Court: Companies cannot obtain patents for human genes
Ruling could allow broader research
Question of the Day
The Supreme Court on Thursday ruled unanimously that human genes are “a product of nature” and companies cannot obtain patents on them — a major shift in patent policy that could open the door to broader medical research on certain cancers and other diseases.
The decision threw out patents awarded to Myriad Genetics Inc., a Utah firm that isolated the location and sequence of what’s known as the BRCA gene, which can signal risk of developing breast and ovarian cancer.
“To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention,” Justice Clarence Thomas wrote for the court.
But the ruling also held that genes the companies create themselves, which Myriad call cDNA, can be patented. The high court left the door open to Myriad and other companies that seek patents for the methods they employ to manipulate genes.
Advocates said prohibiting patents of genes could make tests more affordable by spurring competition among entities that want to test for high-risk gene mutations.
Actress Angelina Jolie recently called attention to the issue by having a preventive double mastectomy because she carries the mutated gene that makes her highly vulnerable to breast cancer.
Myriad’s shares soared Thursday immediately after the ruling but took a dive later in the day, an indication that investors were still trying to digest the mixed ruling. In a statement, the Salt Lake City company highlighted court’s ruling that engineered genes could be patented.
“We believe the court appropriately upheld our claims on cDNA, and underscored the patent eligibility of our method claims, ensuring strong intellectual property protection for our test moving forward,” Myriad President and CEO Peter D. Meldrum said.
But the Association for Molecular Pathology, the lead petitioners in the case against Myriad, also hailed the decision as a boon for scientific research.
“The Court’s decision that human genes are not patentable is a great step forward for the field of molecular pathology, for genomic science, and most important for our patients,” the group said.
Justice Thomas’ opinion, underscoring the esoteric nature of the topic, was heavy with jargon such as “eons,” “messenger RNA” and “nucleotides.” It also delved into the history of human genome research and the “double-helix” that British researchers James Watson and Francis Crick first mapped in 1953.
Justice Antonin Scalia filed a concurring opinion saying he was unable to get into the “fine details of molecular biology” but was confident the DNA that Myriad isolated is identical to the material in its natural state, so it cannot be patented.
Mary Anthony Merchant, a patents specialist at the Ballard Spahr law firm’s Atlanta office, said the court’s interpretation of what it means to isolate something from nature could produce a “ripple effect” among patents on products derived from naturally occurring substances.
“That word ‘isolated’ was kind of magic language at the patent office,” she said. “It was implied, in ‘isolated,’ that you were doing something to do it.”
Various interest groups, including ones that often do not see eye to eye, reacted positively to the court’s decision.
© Copyright 2014 The Washington Times, LLC. Click here for reprint permission.
About the Author
Tom Howell Jr. covers politics for The Washington Times. He can be reached at email@example.com.
- U.S. woman with Ebola is stable, improving, son says
- U.S. surgeon general is hesitant about green-lighting marijuana
- Senators to FIFA, others: Don't reward Putin with the World Cup in 2018
- Ohio Gov. John Kasich cruising to re-election: survey
- GOP seizes on Alison Lundergan Grimes' odd 'Iron Dome' comments
Latest Blog Entries
TWT Video Picks
- Geraldo Rivera: Matt Drudge 'doing his best to stir up a civil war'
- Lois Lerner hated conservatives, new emails show
- Catholic League slams Obama: 'Do Christian lives mean so little to you?'
- HURT: Impeaching Obama is a losing strategy for the GOP
- CARSON: Rudderless U.S. foreign policy
- Patent workers paid to exercise, shop, do chores: report
- Federal judge grants 90-day stay in D.C. gun case
- Fla. mom arrested for allowing 7-year-old son to walk to park alone
- Senate overcomes first filibuster of Obama's border-spending bill
- Obama thanks Muslims for 'building the very fabric of our nation'
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world